Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07478952 |
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age |
RECRUITING | PHASE1 |
| NCT06926894 |
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults |
RECRUITING | PHASE1 |
| NCT06480903 |
Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy |
NOT_YET_RECRUITING | |
| NCT06426758 |
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation |
NOT_YET_RECRUITING | |
| NCT06131489 |
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement |
NOT_YET_RECRUITING | |
| NCT05815108 |
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome |
COMPLETED | |
| NCT05775705 |
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH |
NOT_YET_RECRUITING | PHASE3 |
